There were significant within-treatment differences (ANOVA) for both cyclophosphamide (F = 8.38; P £ 0.05) and vinblastine sulfate (F = 8.54; P £ 0.05), and also when compared with their respective control group. The Student-Newman-Keuls test indicated that the cyclophosphamide doses of 4 and 32 mg/kg body weight did not alter the frequency of MN compared to the control, whereas the other doses (8 and 16 mg/kg body weight) significantly increased the frequency of MN. The frequencies of MN for cyclophosphamide concentrations of 8 and 32 mg/kg body weight were similar and did not differ significantly to the values observed with the dose of 4 mg/kg body weight. Likewise, the responses to 8 and 16 mg/kg body weight were also similar. There were no significant differences in the frequency of MN among the different doses of vinblastine sulfate used. However, the MN frequencies with all of the doses were significantly higher than in the control group. DISCUSSION Cytogenetic methods are probably the ...
Vinblastine Sulfate Pharmachemie is a medicine available in a number of countries worldwide. A list of US medications equivalent to Vinblastine Sulfate Pharmachemie is available on the Drugs.com website.
Vinblastine sulfate definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now!
LGM Pharma is a Vinblastine Sulfate CAS# 143-67-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity and more.
3S CORPORATION - Supplier, Exporter, Distributor of Navelbine Vinorelbine 10 mg Injection from Mumbai, Maharashtra, India. Buy best quality of Navelbine Vinorelbine 10 mg Injection from us.
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days ...
An online friend told me that she was on Navelbine together with Avastin for about a year and a half with great results and almost no side effects. The Navelbine and Avastin stopped the cancer in its tracks and got her to stable disease. She found it to be very tolerable, the easiest regimen of any shed been on. ...
Concomitant platinum-based chemotherapy and radiotherapy (CT-RT) is the recommended treatment for unresectable locally advanced stage III non-small cell lung cancer (NSCLC). We conducted a phase II study to evaluate the efficacy and safety of fractionated oral vinorelbine with cisplatin as induction CT followed by CT-RT. Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. Responding patients received 2 more cycles of cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 concomitantly with radiotherapy 2 Gy daily, 5 days/week for a total of 66 Gy. Seventy patients, median age 61 years, were enrolled. Overall response rate (ORR) was 50.0%; Disease Control Rate was 81.42%. Median PFS was 14.58 months [95% CI, 10.97-18.75]. Median OS was 17.08 months [95% CI, 13.57-29.57]. One-year and 2-year survival rates were 68.6% [95% CI, 57.7-79.4] and 37%. One patient had a grade 3
This study compared the efficacy and tolerability of monotherapy with paclitaxel [Taxol] versus vinorelbine [Navelbine] as first-line therapy in patients with
Reviews Armand JP, Marty M. Navelbine: A new step in cancer therapy? Semin Oncol 1989;16(2; Suppl 4):41-5 (#1371174/2). Barisano A. Vinorelbine: A promising vinca alkaloid for the treatment of lung cancer. P T 1994;19(7):665-6 (94/08896). Cvitkovic E. The current and future place of vinorelbine in cancer therapy. Drugs 1992;44(Suppl 4):36-45 (#4252526/2). Harris Spiridonidis C. Vinorelbine tartrate. Drugs Today 1992;28(3):160-2 (#3588620/2). Pinedo HM, van Groeningen CJ. Vinorelbine: A horse of a different color? J Clin Oncol 1994;12(9):1745-7. Sorensen JB. Vinorelbine: A review of its antitumour activity in lung cancer drugs. Drugs 1992;44(Suppl 4):60-5 (#4252538/2 ...
BioAssay record AID 354662 submitted by ChEMBL: Inhibition of p-glycoprotein expressing human MCF7 cells assessed as [3H]vinblastine accumulation.
This is a phase I/II clinical trial. In phase I part, the primary objective is To determine the recommended dose of the combination of lapatinib with oral vinorelbine in patients with ErbB2 positive metastatic breast cancer. In phase II part, the primary objective is progression free survival of the combination of lapatinib with oral vinorelbine as first line chemotherapy in patients with ErbB2 positive metastatic breast cancer. The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment. In pre-clinical studies, the highest synergism between anti-Her2 treatment (trastuzumab) and cytotoxics was seen with the platinum compounds and with vinorelbine. The oral vinorelbine has similar efficacy to that of the injection formulation and has demonstrated generally favorable ...
The objective of the study was to prepare vinblastine microparticles by supercritical antisolvent process using N-methyl-2-pyrrolidone as solvent and carbon dioxide as antisolvent and evaluate its physicochemical properties. The effects of four process variables, pressure, temperature, drug concentration and drug solution flow rate, on drug particle formation during the supercritical antisolvent process, were investigated. Particles with a mean particle size of 121 ± 5.3 nm were obtained under the optimized process conditions (precipitation temperature 60 °C, precipitation pressure 25 MPa, vinblastine concentration 2.50 mg/mL and vinblastine solution flow rate 6.7 mL/min). The vinblastine was characterized by scanning electron microscopy, X-ray diffraction, Fourier-transform infrared spectroscopy, mass spectrometry and dissolution test. It was concluded that physicochemical properties of crystalline vinblastine could be improved by physical modification, such as particle size reduction and generation
Vinblastine definition, an alkaloid, C 46 H 58 N 4 O 9 , derived from the periwinkle Vinca rosea, used in the treatment of various malignant conditions, especially in the management of lymphomas. See more.
Specialized in the manufacture of Vindoline,2182-14-1,API,This product is synthesis of vinblastine sulfate, vinorelbine, vinblastine and other raw materials for dehydration.
50 µCi quantities of [G-3H]-Vinblastine Sulphate are available for your research. Application of [3H]Vinblastine can be found in: human placental transport and the contribution of P-glycoprotein (P-gp) in pharmacology, oocytes expressing human P-gp (probing trans- and cis-inhibitory effects on efflux) in pharmacology, accumulation of the antimalarial microtubule inhibitors by a major human malarial parasite in biochemical pharmacology, diffusivity and distribution in three-dimensional tumour tissue (experimental and mathematical modelling) in cancer research, etc. ...
Vinblastine - Get up-to-date information on Vinblastine side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Vinblastine
This study investigated the efficacy and tolerability of vinorelbine [Navelbine; Pierre Fabre] + cisplatin, as induction therapy, followed by radiotherapy +
Vinorelbine is cancer medication that interferes with the growth of cancer cells and slows their spread in the body. Vinorelbine is used to treat non-small cell lung cancer. Vinorelbine is sometimes used in combination with other cancer medications. Vinorelbine may also be used for other purposes not listed in this...
non small cell lung cancer Kathy Leslie wrote: , Pardon my ignorance, but whats nsclc? , , [email protected] wrote: , , , I was diagnosed in July 98 with nsclc. I went through 10 chemos (every week , , for 10 weeks) of taxol and carboplatin along with 34 radiation treatments to , , the right lung. After this treatment my surgeon was able to go in and remove , , the tumor. Upon biopsy of the tumor the only thing they found were dead , , cancer cells. The surgeon told me it was obvious the chemo and radiation , , treatments had killed the tumor. Hope this helps. , , , , donna , , ------------------------------------------------------------------------ , , This is an automatically-generated notice. If youd like to be removed , , from the mailing list, please visit the Medicine-On-Line Discussion Forum , , at ,http://www.meds.com/con_faq.html,, or send an email message to: , , [email protected] , , with the subject line blank and the body of the message containing the line: , , unsubscribe ...
Dr G wants me to get Neulasta tomorrow since my white blood cell counts and hematocit were a bit down. That will mean four trips to Capitol Hill this week, three of them for cancer-related reasons. Thankfully this chemo has so far been remarkably tolerable, with minimal side effects, and allows me to drive and generally live a normal life. The jury is out on how effective it will be but I am still hopeful that it will kick some serious cancer butt. I get my next tumor marker drawn next week ...
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. Academic Article ...
Subcellular distribution of mass can be analyzed by a technique that involves culturing cells on interferometers and digitizing their interference contours. Contour sampling resulted in 102 variables per cell, which were predictors of oncogenic transformation. Cell phenotypes can be deconstructed by use of latent factors, which represent the covariance of the real variables. The reversal of the cancertype phenotype by a combination of microtubule- stabilizing and -depolymerizing agents was described previously. The implications of these results have been explored by clinicians who treated patients with the combination of docetaxel and vinorelbine (Navelbine®). The current study was performed to determine the effects of different combinations on phenotype and in phases of the cell cycle other than mitosis. Combinations of paclitaxel with either colchicine, podophyllotoxin, nocodazole, or vinblastine caused phenotype reversal. Paclitaxel analogue, 7-deoxytaxol, by itself caused reversal. Factors #4,
Vinblastine (Alkaban-AQ, Velban) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of multiple cancers
Get an answer for Describe two chemical properties of Vinblastine (anticancer drug) and one benefit to society? and find homework help for other Science questions at eNotes
Reviews and ratings for Vinblastine when used in the treatment of cancer. Share your experience with this medication by writing a review.
Clinical trial for Recurrent Low-grade Gliomas | Refractory Low-grade Gliomas , Study Of Vinblastine in Combination With Nilotinib in Children Adolescents and Young Adults
Find information on Vinblastine in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Going to Homage studios is what made me want to draw comics professionally. When I got home I found inspiration in the very drugs that were making me so sick. A.B.V.D. Adriamycin, Bleomicin, Vinblastine and Dacarbazine, drugs that were being put into my body to kill the Cancer that my body couldnt fight, but were also destroying my body in the process. It was the name Vinblastine that really sparked the idea. Vinblastine just sounded like the gun toting bad ass supper heroes that were becoming so popular in comics at that time. From there, each drug took on a character and I had my mercenary super hero team. I plotted out a story that mirrored what was happening in my body. It took place in a massive space ship constantly fighting of intruding aliens. But the ships defenses are completely unaware that one of its own citizens has mutated and infects the ship from within. When they finally become aware of the threat they are forced to let in a team of people who can kill this Cancer. As the ...
which may be a reason why this trial was positive for a survival benefit but the results from the BMS-099 trial. have been less clearly favorable (a rumor last month of it being positive for survival was wrong and based on miscommunication - we dont have any survival data yet for that).. Regardless, the FLEX trial randomized patients to either cisplatin/navelbine alone or the same chemo with erbitux weekly, and patients who didnt progress after 6 cycles would receive erbitux weekly as a maintenance therapy until progression or serious problematic toxicity. It was reported in the plenary session because it was only the second trial that has shown a significant survival benefit from adding a targeted agent to chemo (the first being avastin), and this is the first that applies to a much broader patient population, since it included patients with a marginal performance status and didnt exclude patients with squamous tumors, on blood thinners, unlike the trial of avastin (although the FLEX trial ...
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline re
In the neoadjuvant group, 218 pts received dd-MVAC and 219 pts GC. The median number of cycles was 6 (0-6) and 4 (1-4), respectively. 60% of pts received 6 cycles in the dd-MVAC arm, 84% received 4 cycles in the GC arm. 199 pts (91%) and 198 (90%) pts underwent surgery, respectively. Complete pathologic responses (ypT0pN0) were observed in 84 (42%) and 71 (36%) pts, respectively (p=0.02). An organ-confined status (,ypT3pN0) was obtained in 154 (77%) and 124 (63%) pts, respectively (p=0.002). In the adjuvant group (57 pts), the median number of cycles was 5 (1-6) and 4 (1-4), respectively. 40% of pts received 6 cycles in the dd-MVAC arm, 60% received 4 cycles in the GC arm. Most of CTCAE grade ≥ 3 toxicities concerned hematological toxicities. At least one of these where reported for 125 (50%) pts in the dd-MVAC group and 134 (54%) pts in the GC group (p=NS). Gastrointestinal (GI) grade ≥ 3 disorders were more frequently observed in the dd-MVAC arm (p,0.0001) as well as grade ≥ 3 asthenia ...
Find the Blink Price & Information for vinorelbine - as low as $874.83 - pick up at your pharmacy (Rite Aid, Walmart & more). Price transparency and up to 80% savings.
See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5-7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin ,3mg/100mL.. ...
Velban belongs to the group of medicines known as antineoplastic agents. It is used to treat certain kinds of cancer, including lymphoma and cancer of the breast or testicles,...
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg t
ALL Manufacturer of Vinorelbine Tartrate for Vinorelbine Tartrate, China vinorelbine tartrate information resources . vinorelbine tartrate Marketplace In Taiwan ,China and Asian Manufacturers,Help you to find more Manufacturers,Suppliers,Exporter,Agent,Global vinorelbine tartrate buyers, vinorelbine tartrate,vinorelbine tartrate Factory.
Microtubules, which are composed of polymerized tubulin dimers, play an important role in various cell functions. For example, they maintain cell shape, form mitotic spindles in M phase of cell cycle, and carry an axonal transport in nerve cells. Microtubules have also been an important target of cancer chemotherapy. Vinca alkaloids depolymerize microtubules, the mechanisms of which action have extensively been investigated recently. Clinical trials of vinorelbine (navelbine), a new semisynthetic vinca alkaloid, are ongoing in Japan. One of advantages of the drug is reduced risk of neurotoxicity. Estramustine may act on microtubule-associated proteins (MAPs) as well as tubulin. It shows additive or synergistic cytotoxicity preclinically when used in combination with vinblastine. This combination was active against hormone-refractory prostate cancer. Another novel drug rhizoxin, which has a similar mechanism of action to that of vinca alkaloids, is also a promising cytotoxic agent and is examined
Get a FREE desacetyl vinblastine amide sulfate coupon and drug savings card and save up to 80% or more on desacetyl vinblastine amide sulfate. Use your desacetyl vinblastine amide sulfate coupon at over 60,000 USA pharmacies.
Get information, facts, and pictures about Vinblastine at Encyclopedia.com. Make research projects and school reports about Vinblastine easy with credible articles from our FREE, online encyclopedia and dictionary.
A drug used to treat breast cancer and choriocarcinoma (a type of gestational trophoblastic tumor) that have not gotten better with other treatment. It is also used to treat Hodgkin lymphoma, non-Hodgkin lymphoma, Kaposi sarcoma, mycosis fungoides, and testicular cancer. It is also being studied in the treatment of other types of cancer. Vinblastine sulfate blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent. The brand name Velban has been taken off the market and is no longer available ...
BETHESDA, Md--Thalidomide, paclitaxel (Taxol), and vinorelbine (Navelbine) have all shown promise in phase II trials as treatment for Kaposis sarcoma in AIDS, researchers reported at the National AIDS Malignancy Conference. Although progress has come in treating KS, more effective drugs are needed, especially in light of the lengthening life span emerging for AIDS patients from the use of drug combinations. 1
From October 1984 through May 1989, 269 patients with advanced urothelial carcinoma were entered onto this international intergroup trial and randomized to receive intravenous (IV) cisplatin (70 mg/m2) alone or with methotrexate (30 mg/m2 on days 1, 15, 22), vinblastine (3 mg/m2 on days 2, 15, 22) plus doxorubicin (30 mg/m2 on day 2). Cycles were repeated every 28 days until tumor progression or a maximum of six cycles. There were 246 fully assessable patients of whom 126 were randomized to cisplatin alone and 120 were randomized to the M-VAC regimen. Results: ...
Microtubule inhibitors such as vinblastine are important anticancer drugs that inhibit the dynamics of microtubules, arrest cells in M phase, and induce subsequent apoptosis. Apoptosis is regulated by Bcl-2 family proteins including the anti-apoptotic protein Mcl-1. Mcl-1 is an important survival factor for many cancers and the expression of Mcl-1 is related to chemo-resistance. In this study, we investigated the role of Mcl-1 in vinblastine-induced apoptosis in KB-3 cells. Vinblastine and other microtubule inhibitors promoted Mcl-1 phosphorylation and subsequent degradation. However, no changes in Mcl-1 phosphorylation or expression were observed when cells were treated with lethal concentrations of DNA-damaging agents, doxorubicin or VP-16, suggesting that these modifications are specific responses to microtubule damage. The degradation of Mcl-1 was inhibited by the proteosome inhibitor MG-132. The phosphorylation of Mcl-1 in synchronized cells was inhibited by treatment with different CDK ...
TY - JOUR. T1 - Chemotherapy of disseminated testicular cancer a random prospective study. AU - Einhorn, Lawrence H.. AU - Williams, Stephen D.. PY - 1980/9/15. Y1 - 1980/9/15. N2 - Seventy-eight patients with disseminated testicular cancer were entered on a random prospective study evaluating 3 separate remission induction arms. Therapy with cis-diamminedichloroplatinum (20 mg/M2 for 5 consecutive days every 3 weeks for 3-4 courses) and bleomycin (30 units intravenous push weekly for 12 consecutive wk) was constant. Patients were allocated at random to one of the following induction regimens (in combination with platinum plus bleomycin): (1) vinblastine 0.4 mg/kg every 3 weeks for 4 courses; (2) vinblastine 0.3 mg/kg every 3 weeks for four courses; or (3) vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every 3 weeks for 4 courses. All patients received maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months (total therapy two years) unless progressive disease intervened. The ...
Stathmin (SMTMN1) normally binds to alpha-beta tubulin heterodimers, but this process is negatively regulated by phosphorylation. In this way phosphorylated Stathmin indirectly promotes polymerization. PDGFRα dephosphorylates STMN1, which leads to increased tubulin depolymerization. Vinblastine inhibits polymerization, effectively resulting in depolymerization. During mitosis, this triggers the defense mechanism "spindle assembly checkpoint" (SAC), which and results in either apoptosis or mitotic slippage ...
KT localization analysis of an extensive hSpindly mutant library consisting of truncation, insertion, deletion, and substitution constructs showed that both the coiled-coil domain II and the C terminus of hSpindly are required for KT localization (Figs. 1 and 2). Although Barisic et al. (2010) has previously shown that the 293-605-aa fragment of hSpindly did not localize to KTs, we found that this specific deletion (N3 construct) does not impair KT localization of hSpindly (Fig. 1). This discrepancy could be the result of overexpression, differences in fusion tags, or the sensitivity of the two assays. Overexpression of coiled-coil proteins often results in aggregation, which can lead to mislocalization of the protein, resulting in a false negative. Immunostaining with anti-FLAG antibody to analyze KT localization by Barisic et al. (2010) compared with GFP fusion constructs may influence the detection sensitivity and our assay is maximized for sensitivity with vinblastine treatment. Barisic et ...
The pharmacokinetics and metabolism of Navelbine (NVB) were investigated in 20 patients by a specific high performance liquid chromatographic methodology allowing the monitoring of NVB, deacetyl-NVB, and N-oxide NVB. After the i.v. (15 min) administration of 30 mg/m2 of drug, blood and urine samples were collected for, respectively, 144 and 48 h. NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 ± 139 (SEM) ng/ml. The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 ± 0.09 liter/h/kg (48.6 ± 4.1 liters/h/m2) and 75.6 ± 9.2 liters/kg (2918.4 ± 307.2 liters/m2). No metabolite could be detected in serum; the urinary excretion of NVB represented 11% of the administered dose. Deacetyl-NVB could be identified as a minor urinary metabolite when no N-oxide NVB appeared in the urine samples. Two additional peaks appeared in most of urinary chromatograms as trace amounts. Thus, the major pathway of NVB, ...
... - Browse fuzing.com to find vinorelbine tartrate sellers, suppliers, wholesalers, companies, manufacturers, exporters, factories.
Labeling of HDs is an extremely important aspect of personnel safety. Without adequate HD labeling, personnel are placed at risk of accidental exposure to HDs. All HDs should be labeled clearly with chemotherapy warning labels. Injectable HD agents should be labeled as "opened" or "reconstituted" on a specific date and the concentration of the reconstituted agent should be indicated. "Look-alike, sound-alike" describes drugs that are spelled and pronounced similarly but are different. The term came about in response to errors involving inadvertent misfills of drugs, for example, vincristine being confused with vinblastine. A simple practice that many pharmacies now follow is arranging their medication stock alphabetically by generic name using a "Tall Man Lettering System." This is a simple way to emphasize spelling and pronunciation differences between drugs (e.g., vincristine is written as vinCRIStine and vinblastine is written as vinBLAStine). Appropriate labeling of mixed chemotherapies can ...